Human Ex-Vivo Liver Model for Acetaminophen-induced Liver Damage
Thomas Schreiter(Universitätsklinikum Knappschaftskrankenhaus Bochum), Ali Canbay(Universitätsklinikum Knappschaftskrankenhaus Bochum), Jan‐Peter Sowa(Universitätsklinikum Knappschaftskrankenhaus Bochum), Guido Gerken, Martin Schlattjan(University of Duisburg-Essen), Hideo A. Baba(Essen University Hospital), Gavin E. Arteel(University of Pittsburgh), Margarete Odenthal(University of Cologne), Robert K. Gieseler, Andreas Paul(Essen University Hospital), Karl-Heinz Strucksberg(University of Duisburg-Essen), Jürgen Treckmann(Essen University Hospital)
Cited by 24
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3
|Journal of Clinical Investigation|2004|620
HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3
|Journal of Clinical Investigation|2004|598
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Non‐alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis
|International Journal of Cancer|2010|520